QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
QQQ   305.97 (+0.20%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NASDAQ:XENE

Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

$34.60
+1.01 (+3.01%)
(As of 03/20/2023 05:18 PM ET)
Add
Compare
Today's Range
$33.38
$34.80
50-Day Range
$33.59
$40.35
52-Week Range
$24.94
$41.39
Volume
180,440 shs
Average Volume
401,863 shs
Market Capitalization
$2.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.70

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.5% Upside
$50.70 Price Target
Short Interest
Bearish
5.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Xenon Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$711,199 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.87) to ($3.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

547th out of 988 stocks

Pharmaceutical Preparations Industry

252nd out of 482 stocks


XENE stock logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Xenon Pharmaceuticals Earnings Preview
Where Xenon Pharmaceuticals Stands With Analysts
Earnings Preview: Xenon Pharmaceuticals
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings
3/01/2023
Today
3/20/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
149
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.70
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+46.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-125,370,000.00
Net Margins
-862.06%
Pretax Margin
-1,327.70%

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$11.54 per share

Miscellaneous

Free Float
59,218,000
Market Cap
$2.18 billion
Optionable
Optionable
Beta
1.37

Key Executives

  • Ian C. Mortimer
    President, Chief Executive Officer & Director
  • Sherry Aulin
    Chief Financial Officer
  • Sheila M. Grant
    Executive VP-Research & Development Operations
  • Christopher KenneyChristopher Kenney
    Chief Medical Officer
  • Robin Sherrington
    Executive Vice President-Strategy & Innovation













XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2023?

12 Wall Street research analysts have issued twelve-month target prices for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $45.00 to $60.00. On average, they expect the company's share price to reach $50.70 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2023?

Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of the year. Since then, XENE shares have decreased by 12.2% and is now trading at $34.60.
View the best growth stocks for 2023 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings data on Wednesday, March, 1st. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.01. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative trailing twelve-month return on equity of 17.90%. The company's revenue was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.57) EPS.

What other stocks do shareholders of Xenon Pharmaceuticals own?
What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Driehaus Capital Management LLC (7.49%), Marshall Wace LLP (3.78%), Lord Abbett & CO. LLC (3.40%), Braidwell LP (2.48%), Point72 Asset Management L.P. (1.88%) and Millennium Management LLC (0.95%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $34.60.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.18 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

The company employs 149 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 3/20/2023 by MarketBeat.com Staff